Search research articles
Contact Us
Filters
Showing results (201-210 of 238) with videos related to
Page
of 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Theodore W Laetsch, Shannon L Maude, Susana Rives, et al.
The New England Journal of Medicine
|
April 25, 2024
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Haydar Frangoul, Franco Locatelli, Akshay Sharma, et al.
Nature Biomedical Engineering
|
August 25, 2025
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells
Tomasz M Grzywa, Alexandra Neeser, Ranjani Ramasubramanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Nature Communications
|
April 23, 2025
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
Pablo Domizi, Jolanda Sarno, Astraea Jager, et al.
Cancer Discovery
|
April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T Teachey, Simon F Lacey, Pamela A Shaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2021
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
John E Levine, Stephan A Grupp, Michael A Pulsipher, et al.
Transplantation and Cellular Therapy
|
March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Muna Qayed, Urvi Kapoor, Scott Gillespie, et al.
Blood Advances
|
November 13, 2019
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
Peter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, et al.
Page
of 24
Search research articles
Search
Showing results (201-210 of 238) with videos related to
Sort By:
Page
of 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2022
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
Theodore W Laetsch, Shannon L Maude, Susana Rives, et al.
The New England Journal of Medicine
|
April 25, 2024
Exagamglogene Autotemcel for Severe Sickle Cell Disease
Haydar Frangoul, Franco Locatelli, Akshay Sharma, et al.
Nature Biomedical Engineering
|
August 25, 2025
Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells
Tomasz M Grzywa, Alexandra Neeser, Ranjani Ramasubramanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2022
Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19
Caroline Diorio, Rawan Shraim, Regina Myers, et al.
Nature Communications
|
April 23, 2025
IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignancies
Pablo Domizi, Jolanda Sarno, Astraea Jager, et al.
Cancer Discovery
|
April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T Teachey, Simon F Lacey, Pamela A Shaw, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL
Regina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2021
Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
John E Levine, Stephan A Grupp, Michael A Pulsipher, et al.
Transplantation and Cellular Therapy
|
March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Muna Qayed, Urvi Kapoor, Scott Gillespie, et al.
Blood Advances
|
November 13, 2019
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
Peter Bader, Emilia Salzmann-Manrique, Adriana Balduzzi, et al.
Page
of 24